TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

SHIONOGI INC

Infectious DiseaseGastroenterologyMetabolic
Specialty

SHIONOGI INC is a specialty pharmaceutical company focused on Infectious Disease, Gastroenterology, Metabolic. Key products include FETROJA.

1993
Since
8
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

FETROJA
cefiderocol sulfate tosylate
4 indications · 2019

Recent Activity

FETROJA 2025-06-06
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 74%
1 drugs Phase 3: 3 Phase 2: 5 Phase 1: 1
Gastroenterology 10%
0 drugs Phase 2: 1 Phase 1: 2
Metabolic 10%
0 drugs Phase 2: 1 Phase 1: 2
Oncology 5%
0 drugs Phase 1: 2

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Gastroenterology
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Johnson & Johnson big-pharma
Oncology, Infectious Disease, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Infectious Disease
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology, Infectious Disease